AU748442B2 - Vertebrate telomerase genes and proteins and uses thereof - Google Patents

Vertebrate telomerase genes and proteins and uses thereof Download PDF

Info

Publication number
AU748442B2
AU748442B2 AU82854/98A AU8285498A AU748442B2 AU 748442 B2 AU748442 B2 AU 748442B2 AU 82854/98 A AU82854/98 A AU 82854/98A AU 8285498 A AU8285498 A AU 8285498A AU 748442 B2 AU748442 B2 AU 748442B2
Authority
AU
Australia
Prior art keywords
telomerase
nucleic acid
acid molecule
sequence
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU82854/98A
Other languages
English (en)
Other versions
AU8285498A (en
Inventor
David Bowtell
Andrzej Kilian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CAMBIA
Original Assignee
Peter MacCallum Cancer Institute
Monticello Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter MacCallum Cancer Institute, Monticello Group Ltd filed Critical Peter MacCallum Cancer Institute
Publication of AU8285498A publication Critical patent/AU8285498A/en
Assigned to Monticello Group, Ltd., The, PETER MACCALLUM CANCER INSTITUTE, THE reassignment Monticello Group, Ltd., The Alteration of Name(s) of Applicant(s) under S113 Assignors: CAMBIA BIOSYSTEMS LLC, PETER MACCALLUM CANCER INSTITUTE, THE
Application granted granted Critical
Publication of AU748442B2 publication Critical patent/AU748442B2/en
Assigned to CAMBIA reassignment CAMBIA Alteration of Name(s) in Register under S187 Assignors: Monticello Group, Ltd., The, PETER MACCALLUM CANCER INSTITUTE, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU82854/98A 1997-07-01 1998-07-01 Vertebrate telomerase genes and proteins and uses thereof Ceased AU748442B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US5141097P 1997-07-01 1997-07-01
US60/051410 1997-07-01
US5301897P 1997-07-21 1997-07-21
US5332997P 1997-07-21 1997-07-21
US60/053018 1997-07-21
US60/053329 1997-07-21
US5464297P 1997-08-04 1997-08-04
US60/054642 1997-08-04
US5828797P 1997-09-09 1997-09-09
US60/058287 1997-09-09
PCT/US1998/013835 WO1999001560A1 (en) 1997-07-01 1998-07-01 Vertebrate telomerase genes and proteins and uses thereof

Publications (2)

Publication Number Publication Date
AU8285498A AU8285498A (en) 1999-01-25
AU748442B2 true AU748442B2 (en) 2002-06-06

Family

ID=27535157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82854/98A Ceased AU748442B2 (en) 1997-07-01 1998-07-01 Vertebrate telomerase genes and proteins and uses thereof

Country Status (9)

Country Link
US (3) US6916642B1 (enExample)
EP (1) EP0917579A1 (enExample)
JP (1) JP2002514928A (enExample)
KR (1) KR100581990B1 (enExample)
CN (1) CN1270634A (enExample)
AU (1) AU748442B2 (enExample)
CA (1) CA2294782A1 (enExample)
IL (1) IL133830A0 (enExample)
WO (1) WO1999001560A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6777203B1 (en) 1997-11-19 2004-08-17 Geron Corporation Telomerase promoter driving expression of therapeutic gene sequences
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
CA2294782A1 (en) * 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
WO1999027113A1 (en) * 1997-11-26 1999-06-03 Geron Corporation Mouse telomerase reverse transcriptase
EP1045027B1 (en) * 1998-01-08 2006-05-31 Chugai Seiyaku Kabushiki Kaisha Novel gene having reverse transcriptase motif
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
DE19916929A1 (de) * 1999-04-15 2000-10-19 Bayer Ag Ein automatisierbarer Schnelltest zum Nachweis von Krebserkrankungen auf der Basis von Telomerase(hTC) mRNA mit spezifischen Primern und Sonden
US6912492B1 (en) 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6210950B1 (en) * 1999-05-25 2001-04-03 University Of Medicine And Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6664046B1 (en) 1999-12-16 2003-12-16 Roche Molecular Systems, Inc. Quantitation of hTERT mRNA expression
KR20010096991A (ko) * 2000-04-19 2001-11-08 임정빈 텔로머레이즈의 프로모터에 특정하게 결합하는더블유티이1 절편, 그 유전자, 발현벡터 및 그것을 이용한세포성장 억제 방법
AUPQ923400A0 (en) * 2000-08-07 2000-08-31 Children's Medical Research Institute Assays for alternative lengthening of telomeres
US7078491B1 (en) 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
EP1440085B8 (de) * 2001-10-18 2010-08-04 Medicyte GmbH Transiente immortalisierung von zellen durch onkogenproteine oder telomerproteine
US20060127909A1 (en) * 2002-12-06 2006-06-15 Bernd Schwenzer Polynucleotides targeted against hter and use thereof
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
US9657068B2 (en) 2010-02-16 2017-05-23 Ultimovacs As Telomerase polypeptide vaccine for treating cancer
RU2468030C2 (ru) 2010-04-09 2012-11-27 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Ингибиторы теломеразы и способ их получения
CN108841802B (zh) 2012-05-11 2023-06-09 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
KR101873773B1 (ko) 2012-05-11 2018-08-02 주식회사 젬백스앤카엘 류마티즘 관절염 예방 또는 치료 조성물
JP6272853B2 (ja) 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
JP6517692B2 (ja) * 2012-09-19 2019-05-22 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
EP2970990B1 (en) * 2013-03-15 2018-07-18 Monsanto Technology LLC Compositions and methods for the production and delivery of rna
WO2014171792A1 (ko) * 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
EP4063863A1 (en) 2013-06-07 2022-09-28 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
CN105324123B (zh) 2013-06-21 2022-02-08 珍白斯凯尔有限公司 激素分泌调节剂、包含该调节剂的组合物、和利用其控制激素分泌的方法
US9757473B2 (en) * 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
CN110755599A (zh) 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
ES2908096T3 (es) 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
WO2017070237A1 (en) * 2015-10-19 2017-04-27 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN110117644A (zh) * 2019-04-18 2019-08-13 王金固 一种用于生物样本中rna的基因检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5645986A (en) 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5972605A (en) 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
ATE308554T1 (de) * 1994-07-07 2005-11-15 Geron Corp Säugetier-telomerase
WO1996019580A2 (en) * 1994-12-19 1996-06-27 Cold Spring Harbor Laboratory Telomerase protein component
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) * 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
CA2294782A1 (en) * 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof

Also Published As

Publication number Publication date
US20050176022A1 (en) 2005-08-11
KR100581990B1 (ko) 2006-05-23
WO1999001560A1 (en) 1999-01-14
EP0917579A1 (en) 1999-05-26
CA2294782A1 (en) 1999-01-14
JP2002514928A (ja) 2002-05-21
IL133830A0 (en) 2001-04-30
AU8285498A (en) 1999-01-25
CN1270634A (zh) 2000-10-18
US6916642B1 (en) 2005-07-12
KR20010020601A (ko) 2001-03-15
US6846662B1 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
AU748442B2 (en) Vertebrate telomerase genes and proteins and uses thereof
US6043083A (en) Inhibitors of the JNK signal transduction pathway and methods of use
Kermouni et al. The IL-9 receptor gene (IL9R): genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter
Laverty et al. Murine CASK is disrupted in a sex-linked cleft palate mouse mutant
US6300110B1 (en) Peptides related to TPC2 and TPC3, two proteins that are coexpressed with telomerase activity
AU745420B2 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
US6277979B1 (en) KIAA0551 polynucleotides and polypeptides use
US6586577B2 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
US20040142357A1 (en) Novel telomerase inhibitors and uses therefor
Shirsat et al. Structure of the murine lactotransferrin gene is similar to the structure of other transferrin-encoding genes and shares a putative regulatory region with the murine myeloperoxidase gene
Kelter et al. The transcription factor-like nuclear regulator (TFNR) contains a novel 55-amino-acid motif repeated nine times and maps closely to SMN1
WO2000061813A1 (en) A second mammalian tankyrase
EP1571215A2 (en) Vertebrate telomerase genes and proteins and uses thereof
US6815532B2 (en) ATR-2 cell cycle checkpoint
CA2324445A1 (en) Blk genes, gene products and uses thereof in apoptosis
MXPA00000196A (en) Vertebrate telomerase genes and proteins and uses thereof
EP1364025B1 (en) A novel gene bno1 mapping to chromosome 16q24.3
HK1032074A (en) Vertebrate telomerase genes and proteins and uses thereof
WO2002026246A2 (en) Pharmaceutical compositions comprising polynucleotides encoding a raf protein
CA2261297A1 (en) A novel maturation-inhibited protein kinase
JP2001245669A (ja) 新規シチジンデアミナーゼ
JP2003088376A (ja) ヒト・キナーゼｍａｓｋとその遺伝子

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE NAME OF THE APPLICANT IN REGARD TO PATENT APPLICATION NUMBER 82854/98 SHOULD INCLUDE: PETER MACCULLUM CANCER INSTITUTE

PC1 Assignment before grant (sect. 113)

Owner name: THE MONTICELLO GROUP, LTD., PETER MACCULLUM CANCER

Free format text: THE FORMER OWNER WAS: CAMBIA BIOSYSTEMS LLC, PETER MACCULLUM CANCER INSTITUTE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND 2ND APPLICANT'S NAME TO READ: PETER MACCALLUM CANCER INSTITUTE

FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PROVIDE SEARCH RESULTS UNDER S45(3) HAS BEEN EXTENDED TO 20040301